Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Citarinostat |
Synonyms | |
Therapy Description |
Citarinostat (ACY-241) selectively inhibits HDAC6, which potentially results in decreased tumor cell viability and reduced tumor growth, particularly in combination with other agents (PMID: 27926524, PMID: 28264055, PMID: 32394008). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Citarinostat | ACY-241|CC-96241 | HDAC Inhibitor 45 | Citarinostat (ACY-241) selectively inhibits HDAC6, which potentially results in decreased tumor cell viability and reduced tumor growth, particularly in combination with other agents (PMID: 27926524, PMID: 28264055, PMID: 32394008). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02551185 | Phase I | Citarinostat | ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02400242 | Phase I | Citarinostat Dexamethasone Pomalidomide | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | Terminated | USA | GRC | FRA | ESP | DEU | 0 |